Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 21Aug 26Aug 31Sep 3Sep 8Sep 11Sep 16Sep 21

Key dataSep 21, 2026

OpenCNY 12.12

From 52W high−19.47%

Volume2.39M

Market capCNY 7.39B

P/E (TTM)17.1x

P/S (TTM)3.4x

Div yield4.13%

Key dataSep 21, 2026

Open

CNY 12.12

From 52W high

−19.47%

Volume

2.39M

Market cap

CNY 7.39B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.1x

P/E (TTM)

17.1x

RSI (14)

33.8

MomentumView details →

1D Return

−4.99%

YTD Return

−14.11%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

17.1x

EV/EBITDA

10.1x

EV/Sales

3.0x

P/S (TTM)

3.4x

P/B (TTM)

2.3x

ProfitabilityView details →

Gross Margin

77.20%

Net Margin

21.51%

EBITDA Margin

30.15%

ROE (TTM)

13.62%

ROA (TTM)

10.48%

Asset Turnover

0.49x

GrowthView details →

Revenue YoY

−3.38%

EPS YoY

−13.89%

FCF YoY

−14.07%

Revenue CAGR 3Y

+1.44%

EPS CAGR 3Y

+9.74%

EBITDA YoY

—

MomentumView details →

1D Return

−4.99%

YTD Return

−14.11%

1Y Return

−17.11%

RSI (14)

33.8

vs 50D SMA

−6.42%

vs 200D SMA

−12.04%

Capital & dividendView details →

Debt/Equity

0.12x

Current Ratio

3.97x

Quick Ratio

3.62x

Div Yield

4.13%

Div Rate

CNY 0.50

Div Growth 1Y

+0.00%

EarningsView details →

EPS (Actual)

CNY 0.23

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

2.10B

Net Income (TTM)

452.67M

Op. CF (TTM)

668.60M

Latest newsMore news →

Guilin Sanjin's wholly-owned subsidiary Hunan Sanjin was provisionally selected in the 12th national centralized drug procurement for lamotrigine tablets, with the procurement period running until December 31, 2029.49d ago

Guilin Sanjin Pharmaceutical Co., Ltd. provided guarantees totaling 60 million yuan for its wholly-owned subsidiaries Baochuan Bio and Baifan Bio to increase their credit lines with Xiamen International Bank Shanghai Branch.56d ago

Similar companies

岱勒新材300700.SZ 博俊科技300926.SZ 秋田微300939.SZ 九芝堂000989.SZ 新莱福301323.SZ 科创新源300731.SZ Find similar companies →

Latest newsMore news →

Guilin Sanjin's wholly-owned subsidiary Hunan Sanjin was provisionally selected in the 12th national centralized drug procurement for lamotrigine tablets, with the procurement period running until December 31, 2029.49d ago Guilin Sanjin Pharmaceutical Co., Ltd. provided guarantees totaling 60 million yuan for its wholly-owned subsidiaries Baochuan Bio and Baifan Bio to increase their credit lines with Xiamen International Bank Shanghai Branch.56d ago